Tukysa (tucatinib) — United Healthcare

Initial criteria

• Diagnosis of unresectable, advanced OR metastatic colorectal cancer (HER2-amplified and RAS and BRAF wild-type)
• Disease is human epidermal growth factor receptor 2 (HER2)-positive
• One of the following: Patient has previously been treated with fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy OR Patient is not appropriate for intensive therapy
• Used in combination with trastuzumab (e.g., Kanjinti, Ogivri, Trazimera)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Tukysa therapy

Approval duration

12 months